Suppressed soluble Fms-like tyrosine kinase-1 production aggravates atherosclerosis in chronic kidney disease

Kidney International

Volumn 85, Issue 2, 2014, Pages 393-403

  Matsui, Masaru ^a   Takeda, Yukiji ^a   Uemura, Shiro ^a   Matsumoto, Takaki ^a   Seno, Ayako ^a   Onoue, Kenji ^a   Tsushima, Hideo ^a   Morimoto, Katsuhiko ^a   Soeda, Tsunenari ^a   Okayama, Satoshi ^a,b   Somekawa, Satoshi ^a   Samejima, Ken Ichi ^a   Kawata, Hiroyuki ^a   Kawakami, Rika ^a   Nakatani, Kimihiko ^a   Iwano, Masayuki ^a   Saito, Yoshihiko ^a,b  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Department of Regulatory Medicine for Blood Pressure ^*  (Japan)

Author keywords

atherosclerosis; chronic kidney disease; placental growth factor; soluble fms like tyrosine kinase 1

Indexed keywords

APOLIPOPROTEIN E; FMS LIKE TYROSINE KINASE 1; HEPARIN; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; HEPARIN LOADING TEST; HUMAN; HUMAN CELL; LOADING TEST; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

ADULT; AGED; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HEPARIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; PREGNANCY PROTEINS; PROGNOSIS; PROTEIN ISOFORMS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84893298755     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.339     Document Type: Article

References (40)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
2. Ninomiya T, Kiyohara Y, Kubo M et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: The Hisayama Study. Kidney Int 2005; 68: 228-236
3. Hillege HL, Fidler V, Diercks GF et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782
4. Hemmelgarn BR, Manns BJ, Lloyd A et al. Alberta Kidney Disease Network: Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-429
5. Schmieder RE, Mann JF, Schumacher H et al. on behalf of the ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353-1364
6. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: 112-119
7. Di Angelantonio E, Chowdhury R, Sarwar N et al. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: Prospective population based cohort study. BMJ 2010; 341: C4986
8. Oemrawsingh RM, Lenderink T, Akkerhuis KM et al. on behalf of the CAPTURE Investigators. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-Term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart 2011; 97: 1061-1066
9. Glaser R, Peacock WF, Wu AH et al. Placental growth factor and B-Type natriuretic peptide as independent predictors of risk from a multibiomarker panel in suspected acute coronary syndrome (Acute Risk and Related Outcomes Assessed with Cardiac Biomarkers (ARROW)) study. Am J Cardiol 2011; 107: 821-826
10. Cassidy A, Chiuve SE, Manson JE et al. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol 2009; 29: 134-139
11. Theilade S, Lajer M, Jorsal A et al. Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy. Diabet Med 2012; 29: 337-344
12. Park JE, Chen HH, Winder J et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not Flk-1/KDR. J Bio Chem 1994; 269: 25646-25654
13. Khurana R, Moons L, Shafi S et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005; 111: 2828-2836
14. Pilarczyk K, Sattler KJ, Galili O et al. Placenta growth factor expression in human atherosclerotic carotid plaques is related to plaque destabilization. Atherosclerosis 2008; 196: 333-340
15. Carmeliet P, Moons L, Luttun A et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-583
16. Selvaraj SK, Giri RK, Perelman N et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003; 102: 1515-1524
17. Roncal C, Buysschaert I, Gerdes N et al. Short-Term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res 2010; 86: 29-36
18. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-10709
19. Park M, Lee ST. The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. Biochem Biophys Res Commun 1999; 264: 730-734
20. Barleon B, Totzke F, Herzog C et al. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 1997; 272: 10382-10388
21. Onoue K, Uemura S, Takeda Y et al. Reduction of circulating soluble fmslike tyrosine kinase-1 plays a significant role in renal dysfunctionassociated aggravation of atherosclerosis. Circulation 2009; 120: 2470-2477
22. Di Marco GS, Reuter S, Hillebrand U et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 2009; 20: 2235-2245
23. Searle J, Mockel M, Gwosc S et al. Heparin strongly induces soluble fmslike tyrosine kinase 1 release in vivo and in vitro-brief report. Arterioscler Thromb Vasc Biol 2011; 31: 2972-2974
24. Onoue K, Uemura S, Takeda Y et al. Usefulness of soluble fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. Am J Cardiol 2009; 104: 1478-1483
25. Sela S, Natanson-Yaron S, Zcharia E et al. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res 2011; 108: 1063-1070
26. Rosenberg VA, Buhimschi IA, Lockwood CJ et al. Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving anticoagulation therapy. Circulation 2011; 124: 2543-2553
27. Drewlo S, Levytska K, Sobel M et al. Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling. J Thromb Haemost 2011; 9: 2486-2497
28. Carroll TY, Mulla MJ, Han CS et al. Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am J Reprod Immunol 2011; 66: 286-296
29. Cachofeiro V, Goicochea M, de Vinuesa SG et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008; 111: S4-S9
30. Annuk M, Zilmer M, Fellström B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease. Kidney Int Suppl 2003; 84: S50-S53
31. Dou L, Bertrand E, Cerini C et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451
32. Meijers BK, Van Kerckhoven S, Verbeke K et al. The uremic retention solute p-cresyl sulfate and markers of endohelial damage. Am J Kidney Dis 2009; 54: 891-901
33. Guo Q, Carrero JJ, Yu X et al. Associations of VEGF and its receptors sVEGFR-1 and-2 with cardiovascular disease and survival in prevalent haemodialysis patients. Nephrol Dial Transplant 2009; 24: 3468-3473
34. Ky B, French B, Ruparel K et al. The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. J Am Coll Cardiol 2011; 19: 386-394
35. Shapiro NI, Schuetz P, Yano K et al. The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care 2010; 14: R182
36. Sela S, Itin A, Natanson-Yaron S et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: Cell-Type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008; 102: 1566-1574
37. Sawano A, Iwai S, Sakurai Y et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocytemacrophages in humans. Blood 2001; 97: 785-791
38. Jin J, Sison K, Li C et al. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell 2012; 151: 384-399
39. Leelahavanichkul A, Huang Y, Hu X et al. Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing high mobility group box protein-1. Kidney Int 2011; 80: 1198-1211
40. Kajimoto H, Kai H, Aoki H et al. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: New effect of asymmetric dimethylarginine. Kidney Int 2012; 81: 762-768